ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING
IL6R>
ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R
(Thomson Reuters ONE) - GHENT, Belgium, 29 June 2009 - Ablynx [Euronext Brussels: ABLX], apioneer in the discovery and development of Nanobodies®, a novelclass of antibody-derived therapeutic proteins, today announced thatit has advanced ALX-0061, a new Nanobody®-based therapeuticprogramme, into preclinical development for the treatment ofautoimmune and inflammatory diseases.ALX-0061 is a selective, low molecular weight biologic, binding tothe IL6 receptor (IL6R). It has a very high potency and demonstrateda favourable PD, PK and safety profile in preclinical testingcompared with the benchmark molecule. ALX-0061 has no Fc-mediatedeffector function which may translate into an improved safetyprofile. It also avoids cross-linking IL6R due to its monovalentbinding to the target.The low molecular weight and desirable biophysical properties of thisNanobody® open up opportunities for alternative routes ofadministration and superior tissue penetration in the clinicalsetting. The Nanobody® can be manufactured at a relatively low costin a microbial system."We are delighted to strengthen our product portfolio by advancinganother novel Nanobody®, discovered using our proprietary Nanobody®platform, into preclinical development. It is well positioned totranslate into a superior treatment for rheumatoid arthritis andother autoimmune diseases. There are already three Nanobodies® inclinical development, with our lead programme, ALX-0081, a novelanti-thrombotic, on track to start Phase II in the next few months",commented Dr. Edwin Moses, Chief Executive Officer and Chairman ofAblynx. -ends-About ALX-0061 (IL6R)ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R).It has the potential to differentiate through its high potency, highstability and low molecule weight of only 26kD which should translateinto superior tissue penetration, attractive PK/PD and superiorsafety and efficacy profile compared with a benchmark monoclonalantibody.The involvement of the IL6 pathway in a variety of diseases indicatesthat multiple indications can be pursued with large market potentialincluding rheumatoid arthritis (RA), Crohn's disease, Castleman'sdisease, multiple myeloma and systemic lupus erythematosus (SLE).For the complete version of the press release, please see link below.For more information, please contact:College Hill Life Sciences - for UK/International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr. Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comhttp://hugin.info/137912/R/1325814/311923.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="NB Private Equity Partners Limited Announces Changes to Liquidity
Enhancement Contract>
">
" alt="AGM Statement>
">
Datum: 29.06.2009 - 12:00 Uhr
Sprache: Deutsch
News-ID 1002394
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 594 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING
IL6R>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
